Related Experiment Video
Updated: Jun 26, 2026
08:47
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
Tissue microarray analysis of eIF4E and its downstream effector proteins in human breast cancer
Heather E Kleiner1, Prasad Krishnan, Jesse Tubbs
1Dept, of Pharmacology, Toxicology, and Neuroscience, Breast Cancer Focus Group, Feist-Weiller Cancer Center, Shreveport & LSUHSC-Shreveport, Louisiana, LA 71130, USA. hklein@lsuhsc.edu
Journal of Experimental & Clinical Cancer Research : CR
|January 13, 2009
Summary
Tissue microarrays (TMAs) efficiently evaluate eukaryotic initiation factor 4E (eIF4E) and its downstream proteins in breast cancer. This method provides results comparable to western blots but is more thorough and efficient for analyzing multiple gene products.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Eukaryotic initiation factor 4E (eIF4E) is upregulated in various cancers, serving as a prognostic marker in breast cancer.
- eIF4E regulates the translation of pro-tumorigenic proteins such as c-Myc, cyclin D1, ODC, VEGF, and TLK1B.
- Traditional western blot analysis for these factors is limited by fresh-frozen tissue availability and labor intensity.
Purpose of the Study:
- To validate the efficiency and thoroughness of tissue microarray (TMA) techniques.
- To compare TMA-based analysis with traditional western blot methods for evaluating eIF4E and its downstream targets in breast cancer.
Main Methods:
- Development and utilization of breast tumor tissue microarrays (TMAs).
- Immunohistochemical staining of TMAs followed by quantitation using the ARIOL imaging system.
- Western blot analysis for comparative validation of eIF4E and TLK1B expression.
Main Results:
- eIF4E levels in TMAs showed strong correlations with c-Myc, cyclin D1, TLK1B, VEGF, and ODC.
- Immunohistochemical findings were consistent with western blot comparisons between eIF4E and TLK1B.
- eIF4E expression did not correlate with established prognostic markers: node status, ER, PR, or HER-2/neu.
Conclusions:
- Tissue microarray (TMA) technique provides results comparable to western blot analysis.
- TMA methodology offers a more efficient and comprehensive approach for evaluating multiple downstream products of eIF4E in breast cancer tissues.
